Table 2.
Sensitivity analyses of clinical outcomes during follow‐up in the entire study cohort of HeartMate 3 vs. HeartWare patients
| Parameter | HeartMate 3 | HVAD | Unadjusted model | PS‐adjusted model | Multivariablea‐adjusted model | |||
|---|---|---|---|---|---|---|---|---|
| n = 106 | n = 258 | HR (95% CI) | P‐value | HR (95% CI) | P‐value | HR (95% CI) | P‐value | |
| Overall mortality, n (%) | 23 (23.6) | 121 (46.9) | 0.66 (0.42–1.02) | 0.059 | 1.08 (0.65–1.80) | 0.773 | 0.99 (0.59–1.67) | 0.975 |
| Stroke, n (%) | 8 (7.5) | 54 (20.9) | 0.43 (0.21–0.92) | 0.028 | 0.54 (0.24–1.26) | 0.155 | 0.58 (0.25–1.34) | 0.205 |
| Driveline infection, n (%) | 42 (39.6) | 131 (50.8) | 0.84 (0.59–1.18) | 0.312 | 0.58 (0.38–0.89) | 0.013 | 0.48 (0.32–0.74) | 0.001 |
| Pump thrombosis, n (%) | 0 (0) | 28 (10.9) | 0.03 (0.01–1.27) | 0.067 | 0.00 (0.00–∞) | 0.941 | 0.00 (0.00–∞) | 0.941 |
CI, confidence interval; HR, hazard ratio; PS, propensity score.
a
Adjusted for age, gender, serum creatinine, Interagency Registry for Mechanically Assisted Circulatory Support level, right heart failure, implant strategy, and time of inclusion after start of recruitment.